Latest revenue
$70.9M
as of 2026-03-31
Latest net income
$-20.0M
as of 2026-03-31
Net margin
-28.3%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ADPT is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.70B
- Enterprise value
- $2.76B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 12.49×
- Dividend yield
- 0.0%
- 52-wk high
- $20.74
- 52-wk low
- $9.90
- Beta
- —
- Shares out
- 160.0M
5-year trend
What this company does
Item 1. Business Overview Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic…
AI summary unavailable — showing raw filing excerpt
Generated from ADPT's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors Investing in our Company involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section, before investing in our Company. Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations, prospects or the trading price of our securities. The risks described below are not the only ones we face and additional risks that we currently do not…
AI summary unavailable — showing raw filing excerpt
Generated from ADPT's filing dated 2026-02-26
Profitability
Operating margin
-20.6%
77.3%Net margin
-21.5%
75.9%Return on equity
-27.2%
65.4%Return on assets
-11.6%
60.8%Leverage
Debt / equity
1.34×
19.1%Long-term debt / equity
0.58×
11.4%Debt / assets
57.3%
8.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $70.9M | +35.1% | $-20.0M | +32.9% | -28.3% |
Q4 2025 2025-12-31 | $71.7M | +51.0% | $-13.6M | +59.7% | -18.9% |
Q3 2025 2025-09-30 | $94.0M | +102.4% | $9.5M | +129.8% | 10.2% |
Q2 2025 2025-06-30 | $58.9M | +36.3% | $-25.6M | +44.6% | -43.5% |
Q1 2025 2025-03-31 | $52.4M | +25.2% | $-29.9M | +37.2% | -56.9% |
Q4 2024 2024-12-31 | $47.5M | — | $-33.7M | — | -71.0% |
Q3 2024 2024-09-30 | $46.4M | +22.5% | $-32.1M | +36.2% | -69.1% |
Q2 2024 2024-06-30 | $43.2M | +460.9% | $-46.2M | +3.3% | -107.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ADPT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$68.2M
Net activity
−$68.2M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ADPT
Institutional value
$828.8M
Total shares held
60.3M
Distinct holders
169
-112 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13.3M | $184.6M | -30.5K (-0.2%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $84.6M | — | New |
| 3 | WESTFIELD CAPITAL MANAGEMENT CO LP | 5.4M | $75.5M | +1.4M (+33.9%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5M | $62.3M | — | New |
| 5 | Invesco Ltd. | 4.5M | $61.8M | +1.3M (+43.2%) | Added |
| 6 | ARK Investment Management LLC | 2.1M | $29.1M | -46.0K (-2.2%) | Trimmed |
| 7 | PRINCIPAL FINANCIAL GROUP INC | 1.7M | $23.7M | +152.4K (+9.8%) | Added |
| 8 | Nikko Asset Management Americas, Inc. | 1.6M | $22.1M | -352.6K (-18.1%) | Trimmed |
| 9 | Sumitomo Mitsui Trust Group, Inc. | 1.6M | $22.1M | -352.6K (-18.1%) | Trimmed |
| 10 | Nuveen, LLC | 1.3M | $18.1M | +517.5K (+65.8%) | Added |
| 11 | Capricorn Fund Managers Ltd | 1.3M | $17.9M | — | New |
| 12 | abrdn plc | 1.1M | $14.9M | +24.1K (+2.3%) | Added |
| 13 | KENNEDY CAPITAL MANAGEMENT LLC | 931.5K | $12.9M | +31.3K (+3.5%) | Added |
| 14 | VANGUARD FIDUCIARY TRUST CO | 871.0K | $12.1M | — | New |
| 15 | DEUTSCHE BANK AG\ | 785.8K | $10.9M | -948.7K (-54.7%) | Trimmed |
| 16 | JENNISON ASSOCIATES LLC | 753.1K | $10.5M | -1.9M (-71.8%) | Trimmed |
| 17 | JANE STREET GROUP, LLC | 682.2K | $9.5M | — | New |
| 18 | Connor, Clark & Lunn Investment Management Ltd. | 649.6K | $9.0M | +58.3K (+9.9%) | Added |
| 19 | Hillsdale Investment Management Inc. | 625.2K | $8.7M | +8.3K (+1.3%) | Added |
| 20 | SEI INVESTMENTS CO | 560.6K | $7.8M | +244.0K (+77.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ADPT's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.